NFKB1 and colorectal carcinoma: To sum up, our findings prove that Bupivacaine inhibits CRC proliferation through blocking the NF-κB signaling pathway activation, promoting apoptosis and autophagy, thus providing strong data support for Bupivacaine as a drug for CRC in the future.